[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY: Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer; 2007 Jul 12;7:127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Medulloblastoma is the most common malignant brain tumor of childhood.
  • TP73 is a member of the TP53 tumor suppressor gene family that has been found to be overexpressed in a variety of tumors and mediates apoptotic responses to genotoxic stress.
  • In this study, we assessed expression of TP73 RNA species in patient tumor specimens and in medulloblastoma cell lines, and manipulated expression of full-length TAp73 and amino-terminal truncated DeltaNp73 to assess their effects on growth.
  • METHODS: We analyzed medulloblastoma samples from thirty-four pediatric patients and the established medulloblastoma cell lines, Daoy and D283MED, for expression of TP73 RNA including the full-length transcript and the 5'-terminal variants that encode the DeltaNp73 isoform, as well as TP53 RNA using quantitative real time-RTPCR.
  • Western immunoblot analysis confirmed their elevated levels of TAp73 and amino-terminal truncated DeltaNp73 proteins.
  • Kaplan-Meier analysis revealed trends toward favorable overall and progression-free survival of patients whose tumors display TAp73 RNA overexpression.
  • Overexpression of TAp73 or DeltaNp73 induced apoptosis under basal growth conditions in vitro and sensitized them to cell death in response to chemotherapeutic agents.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):257-82 [12175339.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Neurosci. 2002 Nov 15;22(22):9800-9 [12427836.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):182-91 [12619104.001]
  • [Cites] Cell Death Differ. 2003 Apr;10(4):431-42 [12719720.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):403-10 [12726865.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4074-81 [12874009.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):487-501 [14701724.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):973-80 [14749764.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):137-40 [14969745.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2449-60 [15059898.001]
  • [Cites] Neuroscientist. 2004 Oct;10(5):443-55 [15359011.001]
  • [Cites] J Neurosci. 2004 Oct 13;24(41):9174-84 [15483136.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4721-3 [1873817.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6316-24 [9774648.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1763-8 [9802988.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1438-49 [9891077.001]
  • [Cites] Neurosci Lett. 1999 Mar 26;263(2-3):173-6 [10213163.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3257-63 [10397274.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4233-6 [10485463.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):546-57 [15548364.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):525-31 [15659498.001]
  • [Cites] BMC Cancer. 2005 Feb 17;5:19 [15717928.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 29;330(1):186-93 [15781249.001]
  • [Cites] Cell Death Differ. 2005 Jul;12(7):805-14 [15877106.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1175-9 [16254107.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8372-83 [16322298.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):805-15 [16380414.001]
  • [Cites] Eur J Neurosci. 2006 Apr;23(8):2109-18 [16630058.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4549-53 [16467208.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):794-803 [16721041.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):804-7 [16921261.001]
  • [Cites] Neurotoxicol Teratol. 2006 Nov-Dec;28(6):664-72 [17095187.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1699-706 [17505515.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] Science. 2000 Jul 14;289(5477):304-6 [10894779.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2696-704 [11352962.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):204-8 [11461077.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):139-51 [11550309.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3796-803 [12032848.001]
  • [Cites] J Neurosci. 2002 Jun 15;22(12):4973-86 [12077194.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • (PMID = 17626635.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS043517; United States / NICHD NIH HHS / HD / T32 HD042977; United States / NICHD NIH HHS / HD / HD042977; United States / NINDS NIH HHS / NS / NS043517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1955450
  •  go-up   go-down


2. Marchetti D, Mrak RE, Paulsen DD, Sinnappah-Kang ND: Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion. J Exp Clin Cancer Res; 2007 Mar;26(1):5-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma (MB) is the most common malignant brain tumor of childhood.
  • NT acts through two groups of structurally unrelated neurotrophin receptors (NTR): a family of receptor tyrosine kinases (Trks, mainly TrkA, TrkB, and TrkC) and a tumor necrosis factor receptor (TNFR)-like molecule called p75NTR TrkC expression is a good prognostic indicator for MB.
  • Importantly, little is known about the biological functions of p75 in primitive neuroectodermal tumors such as MB.
  • In contrast, NT-regulated heparanase (HPSE) is a unique extracellular matrix-degrading enzyme known to be associated with tumor progression in a wide variety of cancers.
  • Taken together, our data provide evidence that HPSE functionality, in a context linked to TrkC and p75NTR activation, may play critical roles in medulloblastoma tumor invasion and progression.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Glucuronidase / metabolism. Medulloblastoma / metabolism. Meningeal Neoplasms / metabolism. Receptors, Nerve Growth Factor / metabolism
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Infant. Male. NF-kappa B / metabolism. Neoplasm Invasiveness. Nerve Tissue Proteins / metabolism. Neurotrophin 3 / metabolism. Neurotrophin 3 / pharmacology. Phosphorylation. Prognosis. Receptor, trkC / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550129.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA086832; United States / NCI NIH HHS / CA / CA103955
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Neurotrophin 3; 0 / Receptors, Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkC; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


3. Andrae J, Molander C, Smits A, Funa K, Nistér M: Platelet-derived growth factor-B and -C and active alpha-receptors in medulloblastoma cells. Biochem Biophys Res Commun; 2002 Aug 23;296(3):604-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignant childhood brain tumor medulloblastoma belongs to the group of primitive neuroectodermal tumours (PNETs).
  • Medulloblastomas are thought to arise from remnants of the transient external germinal layer in the cerebellum.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Platelet-Derived Growth Factor / biosynthesis. Proto-Oncogene Proteins c-sis / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • [MeSH-minor] Cell Differentiation. Cells, Cultured. DNA, Neoplasm / biosynthesis. Dose-Response Relationship, Drug. Humans. Lymphokines. Neurons / cytology. Neurons / metabolism. Proto-Oncogene Proteins c-myc / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. RNA, Neoplasm / biosynthesis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12176024.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Lymphokines; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-myc; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Neoplasm; 0 / platelet-derived growth factor C; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


Advertisement
4. Samano AK, Ohshima-Hosoyama S, Whitney TG, Prajapati SI, Kilcoyne A, Taniguchi E, Morgan WW, Nelon LD, Lin AL, Togao O, Jung I, Rubin BP, Nowak BM, Duong TQ, Keller C: Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Res; 2010 Oct;19(5):829-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is an aggressive childhood cerebellar tumor.
  • Magnetic resonance imaging (MRI) was used to confirm and monitor tumor growth and as an anatomical biomarker for therapeutic response.
  • Wild type mice or medulloblastoma-prone, conditional Patched1 knockout mice were observed by behavioral assays and MRI from postnatal weeks 3-6.
  • Bortezomib treatment was administered during this period and therapeutic response was assessed using cerebellar volumes at the end of treatment.
  • Of the behavioral tests assessed in this study, stride length analysis was best able to detect differences between tumor-prone mice and wild type mice as early as postnatal day 37 (P=0.003).
  • Significant differences between stride lengths of bortezomib treated and control tumor-bearing mice could be detected as early as postnatal day 42 (P=0.020).
  • Cerebellar volumes measured by MRI at the end of treatment validated the therapeutic effects seen by behavioral tests (P=0.03).
  • These findings suggest that stride length analysis may serve as one of the more sensitive and cost-effective method for assessing new therapeutic compounds in this and other preclinical model of brain tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ataxia / etiology. Boronic Acids / therapeutic use. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Protease Inhibitors / therapeutic use. Psychomotor Performance. Pyrazines / therapeutic use. Receptors, Cell Surface / deficiency
  • [MeSH-minor] Animals. Bortezomib. Disease Models, Animal. Disease Progression. Drug Screening Assays, Antitumor / economics. Drug Screening Assays, Antitumor / methods. Gait Disorders, Neurologic / etiology. Lameness, Animal / etiology. Magnetic Resonance Imaging. Mice. Mice, Knockout

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20107895.001).
  • [ISSN] 1573-9368
  • [Journal-full-title] Transgenic research
  • [ISO-abbreviation] Transgenic Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS045879
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Receptors, Cell Surface; 0 / patched receptors; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ NIHMS759162; NLM/ PMC4770905
  •  go-up   go-down


5. Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, Matsumoto K, Mizoguchi M, Ohta M, Iwaki T, Sasaki T: Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol; 2007 Sep;84(2):119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma (MB) is the most common malignant neuroepithelial tumor of childhood.
  • The DNA topoisomerase II (Topo II) inhibitor etoposide has been widely used for the treatment of MBs; however, it remains unknown whether MB cells are more sensitive to etoposide than other malignant neuroepithelial tumor cells.
  • In this study, we tested the chemosensitivities of malignant neuroepithelial tumors (26 glioblastomas, 9 anaplastic astrocytomas, and 5 MBs) to etoposide and vincristine using the succinate dehydrogenase inhibition test and found that MB cells are more sensitive to etoposide and more resistant to vincristine than other tumor cells.
  • In addition, the levels of Topo IIalpha and beta mRNA in these tumors correlated with etoposide sensitivity.
  • Immunohistochemical studies using surgical samples of these tumors demonstrated that the percentages of Topo IIalpha immunopositive cells (Topo IIalpha labeling index) correlated with those of Ki-67 immunopositive cells (MIB-1 labeling index); however, neither the Topo IIalpha nor the MIB-1 labeling index correlated with the levels of Topo IIalpha mRNA or etoposide sensitivity.
  • Based on these observations, Topo IIalpha and beta mRNA expression, but not the Topo IIalpha labeling index, might be a useful marker for sensitivity to etoposide in human malignant neuroepithelial tumors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Cerebellar Neoplasms / genetics. DNA Topoisomerases, Type II / genetics. Drug Resistance, Neoplasm / genetics. Etoposide / therapeutic use. Medulloblastoma / genetics

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 Jan;36(1):41-53 [9525824.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1922-7 [8656261.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] J Med Invest. 2005 Feb;52(1-2):41-8 [15751272.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):499-508 [14585230.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):968-74 [11572765.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5747-53 [11059769.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2247-54 [7666082.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4866-73 [8104687.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):477-82 [10470824.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5330-3 [8968078.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] Mod Pathol. 1999 Dec;12(12):1094-100 [10619260.001]
  • [Cites] Pediatr Neurol. 1997 Oct;17(3):230-4 [9390699.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Childs Nerv Syst. 1997 Nov-Dec;13(11-12):572-7 [9454971.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4726-34 [16034048.001]
  • [Cites] J Neurosurg. 1990 Jan;72(1):96-101 [2294193.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):401-10 [16419060.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Sep;36(9):632-8 [8913079.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):28-32 [9142202.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):325-41 [7619747.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5086-92 [9371507.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):422-7 [8084309.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2048-58 [10473085.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1187-92 [15809708.001]
  • (PMID = 17361331.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / RNA, Messenger; 6PLQ3CP4P3 / Etoposide; 9007-49-2 / DNA; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


6. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA: Survivin splice variants regulate the balance between proliferation and cell death. Oncogene; 2005 Mar 17;24(12):1994-2007
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the diverse functional roles of survivin can be explained, in part, by its heterodimerization with survivin splice variants in tumor cells.
  • Overall, we provide new insights suggesting that targeting specific survivin isoforms, rather than survivin alone, may selectively and effectively destroy tumor cells.
  • These findings are likely to have a significant impact in the design of biologic agents for clinical therapy.
  • [MeSH-major] Alternative Splicing. Cell Death / genetics. Cell Division / genetics. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Apoptosis / genetics. Brain Neoplasms. Cell Line, Tumor. Cerebellar Neoplasms. Genetic Variation. HeLa Cells. Humans. Inhibitor of Apoptosis Proteins. Medulloblastoma. Mitochondria / genetics. Mitochondria / metabolism. Neoplasm Proteins. Polymerase Chain Reaction. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688031.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


7. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD, Kuehl J: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med; 2005 Mar 10;352(10):978-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.
  • We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.
  • In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five-year progression-free and overall survival rates (+/-SE) were 82+/-9 percent and 93+/-6 percent, 50+/-13 percent and 56+/-14 percent, and 33+/-14 percent and 38+/-15 percent, respectively.
  • Desmoplastic histology, metastatic disease, and an age younger than two years were independent prognostic factors for tumor relapse and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Analysis of Variance. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child, Preschool. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Follow-Up Studies. Humans. Infant. Intelligence / drug effects. Methotrexate / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neuropsychological Tests. Postoperative Care. Proportional Hazards Models. Remission Induction. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] Nat Clin Pract Oncol. 2005 Aug;2(8):386-7 [16130930.001]
  • [CommentIn] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15930429.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938011.001]
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938010.001]
  • (PMID = 15758008.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sörensen N, Warmuth-Metz M, Bamberg M: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):269-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
  • PURPOSE: The German Society of Pediatric Hematology and Oncology (GPOH) conducted a randomized, prospective, multicenter trial (HIT '91) in order to improve the survival of children with medulloblastoma by using postoperative neoadjuvant chemotherapy before radiation therapy as opposed to maintenance chemotherapy after immediate postoperative radiotherapy.
  • RESULTS: During chemotherapy Grade III/IV infections were predominant in arm I (40%).
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / drug effects. Bone Marrow Cells / radiation effects. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Drug Administration Schedule. Female. Germany. Humans. Male. Neoplasm Recurrence, Local. Prospective Studies. Radiation Injuries / complications. Radiotherapy Dosage. Survival Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):261-3 [10661329.001]
  • (PMID = 10661332.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Rutkauskiene G, Labanauskas L, Jarusevicius L: The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994-2000. Medicina (Kaunas); 2006;42(1):22-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994-2000.
  • Medulloblastoma, a primitive neuroectodermal tumor growing in cerebellum, is one of the most sensitive to radiation therapy childhood brain tumors, therefore, this method of treatments is justly considered to be the standard for the treatment of medulloblastoma.
  • The outcome of this malignant brain tumor differs in standard and high-risk groups of patients.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Metastasis. Postoperative Care. Prognosis. Radiotherapy Dosage. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467610.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


10. Yu CC, Chiou GY, Lee YY, Chang YL, Huang PI, Cheng YW, Tai LK, Ku HH, Chiou SH, Wong TT: Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity. Childs Nerv Syst; 2010 Jul;26(7):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity.
  • OBJECTS: Medulloblastoma (MB) is the most malignant primary brain tumor in early childhood that contains cellular and functional heterogeneity.
  • Recent evidence has demonstrated that the tumor stem cells (TSC) may explain the radiochemoresistance of brain tumors, including MB.
  • RESULTS: We enrich a subpopulation of MB-TSC cells using tumor spheroid formation approach.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis / radiation effects. Cerebellar Neoplasms / pathology. Drug Resistance, Neoplasm. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Apoptosis Regulatory Proteins / genetics. Cell Line, Tumor. Cell Separation. Cell Survival / drug effects. Cell Survival / radiation effects. Colorimetry. Flow Cytometry. Humans. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2009 Sep;15(9):1010-2 [19734877.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] PLoS One. 2008 May 07;3(5):e2090 [18509505.001]
  • [Cites] Br J Pharmacol. 2006 Jul;148(5):587-98 [16702990.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12687-90 [8663110.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):123-9 [18172261.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):241-2 [18371356.001]
  • [Cites] Childs Nerv Syst. 1995 Feb;11(2):80-4; discussion 85 [7758016.001]
  • [Cites] Nat Rev Drug Discov. 2008 Dec;7(12):1001-12 [18989337.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9 [17307142.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Childs Nerv Syst. 1995 Jun;11(6):340-5; discussion 345-6 [7671269.001]
  • [Cites] Mol Ther. 2009 Feb;17(2):219-30 [19066601.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98 (24):1777-85 [17179479.001]
  • [Cites] Childs Nerv Syst. 2009 May;25(5):543-50 [19225784.001]
  • [Cites] Science. 2009 Jun 26;324(5935):1670-3 [19556499.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] Childs Nerv Syst. 2001 Feb;17(3):121-33 [11305764.001]
  • [Cites] Pediatr Neurol. 1998 Feb;18(2):103-15 [9535295.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):545-54 [18511937.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14 (13):4085-95 [18593985.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8502-6 [15574753.001]
  • [Cites] Biofactors. 2008;34(3):231-5 [19734124.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Curr Gene Ther. 2009 Feb;9(1):9-19 [19275567.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1435-40 [17895479.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • (PMID = 20179950.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


11. Reiss K: Insulin-like growth factor-I receptor - a potential therapeutic target in medulloblastomas. Expert Opin Ther Targets; 2002 Oct;6(5):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastomas represent nearly 25% of all paediatric intracranial neoplasms.
  • These highly malignant tumours arise from the cerebellum and affect predominantly children between the ages of 5 and 15.
  • Taken together, these observations prompt the investigation of different strategies to impair the function of IGF-IR as a potential therapeutic tool, which by compromising growth and survival of medulloblastoma cells could supplement conventional therapeutic regiments against these malignant neoplasms of childhood.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, IGF Type 1 / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Animals. Cell Transformation, Neoplastic / drug effects. Child. Child, Preschool. Humans. JC Virus / pathogenicity. Mice. Polyomavirus Infections / drug therapy. Signal Transduction / drug effects. Signal Transduction / physiology. Tumor Virus Infections / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12387677.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down






Advertisement